Apr 30 |
Wall Street On Edge Ahead Of Fed Decision, Spotlight Falls On Amazon And AMD Earnings: Analyst Says Stocks Survive 'Fragility Test' As April Ends
|
Apr 30 |
Eli Lilly Non-GAAP EPS of $2.58 beats by $0.09, revenue of $8.77B misses by $160M
|
Apr 30 |
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
|
Apr 30 |
Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
|
Apr 29 |
Why these analysts are bullish on healthcare stocks
|
Apr 29 |
All Eyes Are on Zepbound Sales as Lilly Reports Earnings
|
Apr 29 |
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
|
Apr 29 |
Eli Lilly Q1 Earnings Preview: Weight loss therapies to drive quarterly growth
|
Apr 29 |
UPDATE 2-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows
|
Apr 29 |
Here's How Much Stock Eli Lilly Repurchased in 2023
|